Skip to main content
. 2018 Apr 10;10:47. doi: 10.1186/s13148-018-0486-z

Fig. 2.

Fig. 2

The impact of H19 expression on survival in AML. a Overall survival (OS) among whole-cohort AML patients. b OS among non-APL-AML patients. c OS among cytogenetically normal AML (CN-AML) patients. d Leukemia-free survival (LFS) among whole-cohort AML patients. e LFS among non-APL-AML patients. f LFS among CN-AML patients